Loading clinical trials...
Loading clinical trials...
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
Conditions
Interventions
BIIB093
Placebo
Locations
250
United States
Barrow Neurological Institute
Phoenix, Arizona, United States
Arizona Board of Regents, University of Arizona
Tucson, Arizona, United States
Stanford Stroke Center
Palo Alto, California, United States
University of California Davis Health System
Sacramento, California, United States
UCSD Health-La Jolla
San Diego, California, United States
University of Colorado Hospital
Aurora, Colorado, United States
Start Date
August 29, 2018
Primary Completion Date
August 18, 2023
Completion Date
August 18, 2023
Last Updated
November 25, 2024
NCT06658197
NCT02879123
NCT07253870
NCT05338697
NCT06075628
NCT06094478
Lead Sponsor
Remedy Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions